Novel biologic therapies for psoriasis

Bibliography

• LEBWOHL M: Psoriasis. Lancet (2003) 361:1197–1204.
   PubMed Web of Science ®Google Scholar
• RICHARDS HL, FORTUNE DG, O'SULLIVAN TM et al.: Patients with psoriasis and their compliance with medication.' Am. Acad. Dermatol(1999) 41:581–583.
   Google Scholar
• SINGRI MD, WEST DP: Biologic therapy for psoriasis. The new therapeutic frontier. Arch. Dermatol. (2002) 138:657–663.
   PubMed Web of Science ®Google Scholar
• NATIONAL PSORIASIS FOUNDATION: The research pipeline for Psoriasis. The Bulletin (2000) 31:8–9.
   Google Scholar
• MANSBRIDGE JN, KNAPP AM: Changes in keratinocyte maturation during wound healing.' Invest. Dermatol (1987) 89:253–263.
   PubMed Web of Science ®Google Scholar
• NICHKOLOFF BJ: The immunologic and genetic basis of psoriasis. Arch. Dermatol. (1999) 135:1104–1110.
   PubMed Web of Science ®Google Scholar
• VALDIMARSSON H, BAKER BS, JONSDOTTIR I et al.: Psoriasis: a T-cell mediated autoimmune disease induced by streptococcal superantigens? Immunol. Today (1995) 16:145–149.
   Google Scholar
• KRUEGER JG: Pathogenic interactions of keratinocytes and T-lymphocytes in psoriasis. In: Psoriasis Roenigk HH, Maibach HI (Eds), Marcel Dekker, New York, USA (1998):315–327.
   Google Scholar
• LEBWOHL M, ELLIS C, GOTTLIEB A et al.: Cyclosporin consensus conference: with emphasis on the treatment of psoriasis. J. Am. Acad. Dermatol (1998) 39:464–475.
   PubMed Web of Science ®Google Scholar
• GOTTLIEB SL, GILLEAUDEAU P, JOHNSON R et al.: Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat. Med. (1995) 1:442–447.
   PubMed Web of Science ®Google Scholar
• MARTIN A, GUTIERREZ E, MUGLIA J et al.: A multicentre dose-escalation trial with denileukin diftitox (ONTAK, DAB389IL-2) in patients with severe psoriasis.' Am. Acad. Dermatol. (2001) 45:871–881.
   Google Scholar
• SNOWDEN JA, HEATON DC: Development of psoriasis after syngeneic bone marrow transplant from psoriatic donor: further evidence for adoptive auto-immunity. Br. J. Dermatol. (1997) 137:130–132.
   PubMed Web of Science ®Google Scholar
• KRUEGER JG: The immunological basisfor the treatment of psoriasis with new biological agents.' Am. Acad. Dermatol. (2002) 46:1–23.
   PubMed Web of Science ®Google Scholar
• BAN CHEREAU J, STEINMAN RIVI: Dendritic cells and the control of immunity. Nature (1998) 392:245–252.
   PubMed Web of Science ®Google Scholar
• MCFADDEN J, VALDIMERSSON H, FRY L: Cross reactivity between streptococcal M surface antigen and keratin. Br. Dermatol. (1991) 125(5):443–447.
   PubMed Web of Science ®Google Scholar
• VALDIMERSSON H, SIGMUNDSDOTIR H, JONSDOTTIR I: Is psoriasis induced by streptococcal superantigens and maintained by M-protein-specific T cells that cross react with keratin? Clin. Exp. Immunoi (1997) 107\(Suppl. 1):21–24.
   Google Scholar
• TROWSDALE J, CAMPBELL RD: Complexity in the major histocompatibility complex. Ear.' Immunogenet. (1992) 19:45–55.
   PubMedGoogle Scholar
• MROWIETZ U: Treatment targeted to cell surface epitopes. Clin. Exp. Dermatol. (2002) 27:591–596.
   PubMed Web of Science ®Google Scholar
• MOSMAN TR, SAD S: The expanding universe of T-cell subsets: Thl, Th2 and more. Immunol. Today (1996) 17:138–146.
   PubMedGoogle Scholar
• SCHLAAF JF, BUSLAU M, JOCHUM W et al.: T cells involved in psoriasis vulgaris belong to the Thl subset. Invest. Dermatol. (1994) 102:145–149.
   PubMed Web of Science ®Google Scholar
• FUHLBRIGGE RC, KIEFFER JD, ARMERDING D, KUPPER TS: Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin homing T cells. Nature (1997) 389:978–981.
   PubMed Web of Science ®Google Scholar
• ROBERT C, KUPPER TS: Inflammatoryskin diseases, T cells, and immune surveillance. N Engl.' Med. (1999) 341:1817–1828.
   PubMed Web of Science ®Google Scholar
• GRIFFITHS CEM: Cutaneous leukocyte trafficking and psoriasis. Arch. Dermatol. (1994) 130:494–499.
   PubMed Web of Science ®Google Scholar
• CHANG JC, SMITH LR, FRONING JK et al.: CD28+ T cells in psoriatic lesions preferentially use T-cell receptor V beta 3 and/or V beta 13.1 genes. Proc. Nati Acad. Sci. USA (1994) 91:9282–9286.
   Google Scholar
• MENSSEN A, TROMMLER P, VOLLMER S et al.: Evidence for an antigen specific cellular immune response in skin lesions of patients with psoriasis vulgaris. Immunol. (1995) 155:4078–4083.
   Web of Science ®Google Scholar
• PARREN PW: Preparation of genetically engineered monoclonal antibodies for human immunotherapy. Hum. Antibodies Hybridomas (1992) 3:137–145.
   PubMedGoogle Scholar
• SCHUH JC, MORRISSON PJ: Development of a recombinant growth factor and fusion protein: lessons from GM-CSF. Toxicol. Pathol. (1999) 27:72–77.
   PubMed Web of Science ®Google Scholar
• FRIEDRIKSSON T, LASSUS A, SALDE L: Reproducibility of clinical trials of topical glucocorticosteroids. Int. Dermatol. (1983) 22:536–539.
   PubMed Web of Science ®Google Scholar
• CHRISTOPHERS E, MROWIETZ U: The inflammatory infiltrate in psoriasis. Clin. Dermatol. (1995) 13:131–135.
   PubMed Web of Science ®Google Scholar
• PRINZ J, BRAUN FALCO 0, MEURER M et al.: Chimaeric CD4 monoclonal antibody in treatment of generalized pustular psoriasis. Lancet (1991) 338:320–321.
   Google Scholar
• NICHOLAS IF, CHAMCHICK N, THIVOLET J et al.: CD4 antibody in the treatment of psoriasis. Lancet (1991) 338:321.
   Web of Science ®Google Scholar
• MOREL P, REVILLARD JP, NICHOLAS JF et al.: Anti-CD4 monoclonal antibody therapy in severe psoriasis. I Autoimmun. (1992) 5:465–477.
   PubMed Web of Science ®Google Scholar
• RIZOVA H, NICOLAS JF, MOREL P et al.: The effect of anti-CD4 monoclonal antibody treatment on immunopathological changes in psoriatic skin. Dermatol. Sci. (1994) 7:1–13.
   PubMedGoogle Scholar
• GOTTLIEB AB, LEBWOHL M, SHIRIN S et al.: Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicentre, multidose, placebo-controlled study. Am. Acad. Dermatol. (2000) 43:595–604.
   PubMed Web of Science ®Google Scholar
• CHAU LA, ISO JY, MELROSE J, MADRENAS J: HuM291 (Nuvion), a humanized Fc receptor-nonbinding antibody against CD3, anergizes peripheral blood T cells as partial agonist of the T cell receptor. Transplantation (2001) 71(7):941–950.
   PubMed Web of Science ®Google Scholar
• GRIFFITHS CE: Cutaneous leucocyte trafficking and psoriasis. Arch. Dermatol. (1994) 130:494–499.
   PubMed Web of Science ®Google Scholar
• LEBWOHL M: New Developments in the treatment of psoriasis. Arch. Dermatol. (2002) 138:686–688.
   PubMed Web of Science ®Google Scholar
• LANGLEY R, ROENIGK H, MCCALL C et al.: Phase I results of intravenous MEDI-507 (Siplizumab), an anti-T cell monoclonal antibody, for the treatment of psoriasis. j. Invest. Dermatol. (2001) 117:817 (Abstract).
   Google Scholar
• MATHESON R, BEUTNER K, MCCALL C et al.: Subcutaneous injection of Medi-507 (Siplizumab), an anti-T cell monoclonal antibody for the treatment of psoriasis: Phase I results. J. Invest. Dermatol. (2001) 117:817 (Abstract).
   Google Scholar
• PAPP K, LANGLEY R, MATHESON C et al.: Safety, tolerance, and biological activity of MEDI-507 ( Siplizumab) for the treatment of moderate to sever psoriasis. 60th Annual Meeting of the American Academy of Dermatology New Orleans, Louisiana, USA (22–27 February 2002).
   Google Scholar
• SLAVIK JM, HUTCHCROFT JE, BIERER BE: CD28/CTLA-4 and CD80/ CD86 families: signalling and function. Immunol. Res. (1999) 19:1–24.
   PubMed Web of Science ®Google Scholar
• SCHOPF RE: IDEC-114 ( IDEC). Curc Opin. Invest. Drugs (2001) 2:635–638.
   PubMedGoogle Scholar
• GOTTLIEB A, ABDULGHANI A, TOTORIS R et al.: Results of a single-dose, dose escalating trial of an anti-B7 monoclonal antibody (IDEC114) in patient with psoriasis. J. Invest. Dermatol. (2000) 114:840.
   Google Scholar
• ABRAMS JR, LEBWOHL MG, GUZZO CA et al.: CTLA4Ig-mediated blockade of T-cell co-stimulation in patients with psoriasis vulgaris. j Clin. Invest. (1999) 103:1243–1252.
   PubMed Web of Science ®Google Scholar
• ABRAMS JR, KELLEY SL, HAYES E et al: Blockade of T-lymphocyte stimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. j Exp. Med. (2000) 192:681–694.
   PubMed Web of Science ®Google Scholar
• MROWIETZ U: Treatment targeted to cell surface epitopes. Clin. Exp. Dermatol. (2002) 27:591–596.
   PubMed Web of Science ®Google Scholar
• OWEN CM, HARRISON PV: Successful treatment of severe psoriasis with basiliximab an interleukin-2 receptor monoclonal antibody. Clin. Exp. Dermatol. (2000) 25:195–197.
   PubMed Web of Science ®Google Scholar
• SALIM A, EMMERSON RM, DALZIEL KL: Successful treatment of severe generalized pustular psoriasis with basiliximab (interleukin-2 receptor blocker). Br. J. Dermatol. (2000) 143:1121–1122.
   PubMed Web of Science ®Google Scholar
• MROWIETZ U, ZHU K, CHRISTOPHERS E: Treatment of severe psoriasis with anti-CD 25 monoclonal antibodies. Arch. Dermatol. (2000) 136:675–676.
   PubMed Web of Science ®Google Scholar
• KRUEGER JG, WALTERS IB, MIYAZAWA M et al.: Successful in vivo blockage of CD25 (high affinity interleukin-2-receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J. Am. Acad. Dermatol. (2000) 43:448–451.
   PubMed Web of Science ®Google Scholar
• KIRBY B, GRIFFITHS CEM: Novel immune based therapies for psoriasis. Br. J. Dermatol. (2002) 146:546–551.
   PubMed Web of Science ®Google Scholar
• GOTTLIEB SL, GILLEAUDEAU P, JOHNSON R et al.: Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat. Med. (1995) 1:422–427.
   Google Scholar
• BAGEL J, GARLAND WT, BRENNAN D et al.: Administration of DAB389IL-2 to patients with recalcitrant psoriasis; a double blind Phase Ii multicentre trial. I. Am. Acad. Dermatol. (1998) 38:938–944.
   PubMed Web of Science ®Google Scholar
• MARTIN A, GUTIERREZ E, MUGLIA J et al.: A multicentre dose escalating trial with denileukin diftitox (ONTAK, DAB389IL-2) in patients with severe psoriasis. J. Am. Acad. Dermatol. (2001) 45:871–881.
   PubMed Web of Science ®Google Scholar
• BHUSHAN M, BLEIKER TO, BALLSDON AE et al. Anti E-selectin is ineffective in the treatment of psoriasis: a randomised controlled trial. Br. J. Dermatol. (2002) 146:824–831.
   PubMed Web of Science ®Google Scholar
• SCHLAAK JF, BUSLAU M, JOCHUM W et al.: T cells involved in psoriasis vulgaris belong to the Thl subset. Invest. Dermatol. (1994) 102:145–149.
   PubMed Web of Science ®Google Scholar
• ADORINI L, TREMBLEAU S: Immune deviation towards Th2 inhibits Th-1-mediated autoimmune diabetes. Biorbem. Soc. Trans. (1997) 25:625–629.
   PubMed Web of Science ®Google Scholar
• LHONER ME, KRUEGER J, GOTTLIEB A et al.: Clinical trials of a fully human anti-IL-8 antibody for the treatment of psoriasis. Br. J. Dermatol. (1999) 141:989.
   Google Scholar
• ASADULLAH K, FRIEDRICH M, HANNEKEN S et al.: Effects of systemic interleukin-10 therapy on psoriatic skin lesions: histologic, immunohistologic, and molecular biology findings. J. Invest. Dermatol. (2001) 116:721–727.
   PubMed Web of Science ®Google Scholar
• ASADULLAH K, DOCKE WD, EBELING M et al.: Interleuldn 10 treatment of psoriasis: clinical results of a Phase II trial. Arch. Dermatol. (1999) 135:187–192.
   PubMed Web of Science ®Google Scholar
• REICH K,BRUCK M, GRAFE A et al: Treatment of psoriasis with interleukin-10. .1. Invest. Dermatol. (1998) 111:1235–1236.
   PubMed Web of Science ®Google Scholar
• FRIEDRICH M, DOCKE WD, KLEIN A et al.: Immunomodulation by interleukin-10 therapy decreases the incidence of relapse and prolongs the relapse free interval in psoriasis. Invest. Dermatol. (2002) 118:672–677.
   PubMed Web of Science ®Google Scholar
• MCINNES IB, ILLEI GC, DANNING CL et al: IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis. J. Immunol. (2001) 167:4075–4082.
   PubMed Web of Science ®Google Scholar
• TREPICCHIO WL, OZAWA M, WALTERS IB et al.: Interleuldn-11 therapy selectively downregulates type 1 cytokine proinflammatory pathways in psoriasis in psoriatic lesions. J. Clin. Invest. (1999) 104:1527–1537.
   PubMed Web of Science ®Google Scholar
• GHORESCHI K, THOMAS P, BREIT S et al.: Interleuldn-4 induced immune deviation as therapy for psoriasis. J. Invest. Dermatol. (2001) 117:465 (Abstract).
   Google Scholar
• BALAGON MV, WALSH DS, TAN PL et al.: Improvement in psoriasis after intradermal administration of killed Mycobacterium vaccae. hat. J. Dermatol. (2000) 39:51–58.
   Web of Science ®Google Scholar
• RAYCHAUDHURI SP, FARBER EM, RAYCHAUDHURI SK: Immunomodulatory effects of peptide T on Thl/Th2 cytokines. Int. j Immunopbarmacol. (1999) 21:609–615.
   PubMed Web of Science ®Google Scholar
• MROWIETZ U, CHRISTOPHERS E, ALTMEYER P: Treatment of severe psoriasis with fumaric esters: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference. Br. J. Dermatol. (1999) 141:424–429.
   Google Scholar
• OGIL VIE AL, ANTONI C, DECHANT C et al.: Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br. .1. Dermatol. (2001) 144:587–589.
   Google Scholar
• MARTINEZ F, NOS P, BENLLOCH S, PONCE J: Hidradenitis suppuritiva and crohn's disease: response to treatment with infliximab. haflamm. Bowel Dis. (2001) 7:323–326.
   PubMed Web of Science ®Google Scholar
• KOBBE G, SCHNEIDER P, ROHR U et al.: Treatment of severe steroid refractory acute graft-versus host disease with infliximab, a chimeric human/mouse anti-TNF alpha antibody. Bone Marrow Transplant. (2001) 28:47–49.
   PubMed Web of Science ®Google Scholar
• TAN MH, GORDON M, LEBWOHL 0, GEORGE J, LEBWOHL MG: Improvement of pyoderma gangrenosum and psoriasis associated with Crohn's disease with anti-tumour necrosis factor-a monoclonal antibody. Arch. Dermatal (2001) 137:930–933.
   PubMed Web of Science ®Google Scholar
• KIRBY B, MARSLAND AM, CARMICHAEL AJ, GRIFFITHS CE: Succesful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate. Clin. Exp. Dermatal (2001) 26:27–29.
   PubMed Web of Science ®Google Scholar
• CHAUDHARI U, ROMANO P, MULCAHY LD et al.: Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet (2001) 357:1842–1847.
   PubMed Web of Science ®Google Scholar
• GOTTLIEB AB: Clinical research helps elucidate the role of tumor necrosis factor-alpha (TNF-alpha) in the pathogenesis of Tl-mediated immune disorders: use of targeted immunotherapeutics as pathogenic probes. Lupus (2003) 12:192–196.
   Google Scholar
• LEBWOHL M: New developments in the treatment of psoriasis. Arch. Dermatal (2002) 138:686–687.
   PubMed Web of Science ®Google Scholar
• GOTTLIEB AB, MASUD S, RAMAMURTHI et al: Pharmacodynamic and pharmacokinetic response to anti-tumour necrosis factor monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. Am. Acad. Dermatal (2003) 48:68–75.
   PubMed Web of Science ®Google Scholar
• KEANE J, GERSHON S, WISE RP et al: Tuberculosis associated with infliximab, a tumour necrosis factor alpha-neutralising agent. N Engl. I Med. (2000) 345:1098–1104.
   Web of Science ®Google Scholar
• MAINI RN, BREEDVELD FC, KALDEN JR et al: Therapeutic efficacy of multiple intravenous infusions of anti-tumour necrosis factor alpha monoclonal antibody combined with low dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. (1998) 41:1552–1563.
   PubMed Web of Science ®Google Scholar
• BROWN SL, GREEE MH, GERSHON SK, EDWARDS ET, BRAUN MM: Tumour necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug administration. Arthritis Rheum. (2002) 46:3151–3158.
   PubMed Web of Science ®Google Scholar
• GELFAND JM, BERLIN J, VAN VOORHEES A, MARGOLIS D: Lymphoma rates are low but increased in patients with psoriasis. Arch. Dermatal (2003) 139:1425–1429.
   PubMed Web of Science ®Google Scholar
• SANDBORN WJ, HANAUER SB: Antitumour necrosis factor therapy for inflammatory bowel disease: a review of the agents, pharmacology, clinical results and safety. Inflamm. Bowel Dis. (1999) 5:119–133.
   PubMed Web of Science ®Google Scholar
• ELLMAN MH, MACDONALD PA, HAYES FA: Etanercept as a treatment for diffuse scleroderma: a pilot study. Arthritis Rheum. (2000) 43(Suppl.):S392 (Abstract).
   Google Scholar
• SACHER C, RUBBERT A, KONIG C et al.: Treatment of recalcitrant cicatricial pemphigoid with tumor necrosis factor a antagonist etanercept. Am. Acad. Dermatal (2002) 46:113–115.
   PubMed Web of Science ®Google Scholar
• IGER S, YAMAUCHI P, LOWE NJ: Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Br. Dermatal (2002) 146:118–121.
   PubMed Web of Science ®Google Scholar
• MEASE PJ, GOFFE BS, METZ J et al: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet (2000) 356:385–390.
   PubMed Web of Science ®Google Scholar
• MEASE P, KIVITZ, BURCH F, SIEGEL E, COHEN S, BURGE D: Improvement in disease activity in patients with psoriatic arthritis receiving etanercept (ENBREL): results of a Phase III multicentre clinical trial. (abstract). Arthritis Rheum. (2001) 44:S90 (Abstract 226).
   Google Scholar
• GOTTLIEB AB, LOWE N, MATHESON RT, LEBSACK ME: Efficacy of etanercept in patients with psorasis. Ann. Dermatal Venereal. (2002) 129:1S280.
   Google Scholar
• LEONARDI CL, POWERS JL, MATHESON RT et al.: Etanercept as monotherapy in patients with psoriasis. N. Engl. Med. (2003) 349(21):2014–2022.
   PubMed Web of Science ®Google Scholar
• Etanercept (package insert). Seattle, WA, USA: Immunex Corporation and Wyeth-Ayerst Pharmaceuticals (2002).
   Google Scholar
• SHAKOOR N, MICHALSKA M, HARRIS CA et al.: Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet (2002) 359:579–580.
   PubMed Web of Science ®Google Scholar
• FERRACCIOLI G, MECCHIA F, DI POI E, FABRIS M: Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections. Ann. Rheum. Dis. (2002) 61(4):358–361.
   PubMed Web of Science ®Google Scholar
• DA SILVA AJ, BRICKELMAIER M, MAJEAU GR et al.: Alefacept, an immunomoduatory recombinant LFA-3/ IgG1 fusion protein, induces Cd16 signalling and CD2/CD16-dependent apoptosis of CD2+Immune]. (2002) 168:4462-4471.
   Google Scholar
• MAGILAVY D: Immunopharmacogenetic effects of Amevive ( LFA3-TIP) in chronic plaque psoriasis: selectivity for peripheral memory effector T cells (CD45R0+ over naive (CD45RA+) T cells. Br. Dermatal (1999) 141:990 (Abstract).
   Google Scholar
• MAGILAVY D, KRUEGER CG: The response of chronic plaque psoriasis to Amevive (LFA3TIP) and the selective suppression of peripheral memory/effector T cells (CD45R0+) versus naive T cells (CD45RA+) is linked to serum levels of LFA3TIP. Invest. Dermatal (2000) 114:776.
   Google Scholar
• ELLIS CN, KRUEGER CG: Treatment ofchronic plaque psoriasis by selective targeting targeting of memory effector T lymphocytes. N Engl. I Med. (2001) 345:248–255.
   PubMed Web of Science ®Google Scholar
• KRUEGER GC, PAPP KA, STOUGH DB et al.: A randomised double blind, placebo controlled Phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. I Am. Acad. Dermatal (2002) 47:821–833.
   PubMed Web of Science ®Google Scholar
• LEBWOHL M, CHRISTOPHERS E, LANGLEY R, ORTONNE JP, ROBERTS J, GRIFFITHS CE: An international, randomized, double-blind, Placebo controlled Phase III trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch. Dermatal (2003) 139:719–727.
   PubMed Web of Science ®Google Scholar
• GRIFFITHS CE, RAILAN D, GALLATIN WM, COOPER KD: The ICAM-1/LFA-1 interaction is critical for epidermal Langerhans cell alloantigen presentation to CD4+ T cells. Br. Dermatal (1995) 133:823–829.
   PubMed Web of Science ®Google Scholar
• KRUEGER J, GOTTLIEB A, MILLER B, DEDRICK R, GAROVOY M, WALICKE P: Anti-CD1 la treatment for psoriasis concurrently increases circulating T-cells and decreases plaqueT-cells, consistent with inhibition of cutaneous T-cell trafficking. I Invest. Dermatal (2000) 115:333.
   PubMed Web of Science ®Google Scholar
• GOTTLIEB A, KRUEGER JG, BRIGHT R et al.: Effects of a single dose of humanised monoclonal antibody to CD1la on the immunobiologogy and clinical activity of psoriasis. I Am. Acad. Dermatal (2000) 42:428–435.
   PubMed Web of Science ®Google Scholar
• LEBWOHL M: New developments in the treatment of psoriasis. Arch. Dermatol (2002) 138:686–687.
   PubMed Web of Science ®Google Scholar
• PAPP K, BISSONNETTE R, KRUEGER JG et al.: The treatment of moderate to severe psoriasis with a new anti-CD1la monoclonal antibody. J. Am. Acad. Dermatol (2001) 45:666–674.
   Google Scholar
• LEONARDI CL, GOTTLIEB A, TASHJIAN D et al: Efaluzimab (anti-CD11a): results of a twelve week trial of subcutaneous administration in patients with moderate to severe plaque psoriasis. Poster presented at: The Annual Meeting of the American Academy of Dermatology Washington DC, USA (March 2001).
   Google Scholar
• MENTER A, BISSONNETTE R, GOTTLIEB AB et al.: Efaluzimab (anti-CD1 la): results of a 12 week trial of subcutaneous administration in patients with moderate to severe plaque psoriasis. Poster presented at: The Annual Meeting American Association of Dermatology Washington DC, USA (March 2001).
   Google Scholar
• LEBWOHL M: Continued treatment with efaluzimab (anti-CD1 la) improves outcome in patients with moderate to severe plaque psoriasis. 60th Annual Meeting of the American Academy of Dermatology New Orleans, Louisiana, USA (February 2002).
   Google Scholar
• LEBWOHL M, TYRING SK, HAMILTON TK, TOTH D, GLAZER S, TAWFIK NH: A novel targeted T-cell modulator, efaluzimab, for plaque psoriasis. N. Engl. J. Med. (2003) 349(21):2004–2013.
   PubMed Web of Science ®Google Scholar